A Puerto Rico jury ruled this week that pharmaceutical giant Pfizer, Inc. must pay $1.5 million in damages to Helen Rivera-Adams, a San Juan pharmacist who developed breast cancer after taking Prempro, one of the company's menopause drugs.
After two days of deliberations, San Juan jurors concluded that Pfizer's Wreth unit failed to properly warn Ms. Rivera-Adams or her physicians about the serious health risks associated with the drug. Additionally, the jurors found that the medication, for which Ms. Rivera-Adams had been taking for 19 months, attributed to her developing breast cancer. Ms. Rivera-Adams is now tragically suffering from the late stages of her battle with cancer. Nevertheless, she had continued to emphatically press ahead with the lawsuit, believing it was imperative to warn other women of the grave side effects that can be caused by the Pfizer drug.
In 2002, a study was released by the National Institutes of Health, which concluded that the drug posed an increased risk of cancer, heart attacks, strokes, and other potentially deadly side effects to women. Before the study was released, it was believed that some 6 million women had taken or were currently using Prempro. The drug, which is used to boost hormone levels in women undergoing menopause, helps to treat common menopause symptoms such as hot flashes, irregular menstruation, weight gain and mood swings.
Ms. Rivera-Adams is a pharmacist who owns her own drugstore in San Juan, Puerto Rico. According to court documents, Ms. Rivera-Adams, now 62, had been taking Prempro for 19 months before being she was diagnosed with cancer in January, 2002. Unfortunately Ms. Rivera-Adam's claims against the drug company are quite common. In fact, there remain an estimated 9,000 pending lawsuits against Pfizer's Wyeth unit by other women who attribute their breast cancer from haven previously taken Pfizer's Prempro medication.
If you or someone you know has had similar side effects after taking Prempro, please call the law firm of Freidin Brown, P.A. for a free consultation.